How Clinicians Evaluate Reglan-Related Tardive Dyskinesia

Latest update (2025-07)

From General Health Information to Specific Legal Concerns

If you or a loved one has developed involuntary movements after taking Reglan, you may be concerned about tardive dyskinesia. This condition requires careful clinical assessment to confirm. Building on decades of research into medication-induced movement disorders, this page explains the diagnostic criteria and evaluation steps used by healthcare providers in Washington.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. For patients in Washington who have developed TD after taking Reglan, understanding the statute of limitations is critical for pursuing legal claims, as it sets a strict deadline for filing a lawsuit. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after the drug is discontinued. The condition is caused by prolonged blockade of dopamine receptors in the brain, a mechanism directly linked to metoclopramide's pharmacology. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that Reglan may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Approved Use and Risk of Prolonged Exposure

The approved indications for Reglan are limited to short-term use. For gastroesophageal reflux, treatment is recommended for 4 to 12 weeks, and for diabetic gastroparesis, the maximum duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these limits, many patients have been prescribed Reglan for longer periods, increasing their risk of TD. The labeling explicitly states that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a legal perspective, the adequacy of warnings is a central issue. The boxed warning clearly states that Reglan can cause TD and that the drug should be used for the shortest duration possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, patients may argue that their prescribing physician did not adequately communicate these risks, or that they were not informed about the need for regular monitoring. The labeling also advises that if longer-term use is unavoidable, patients should be routinely monitored for signs of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to follow these recommendations could form the basis of a negligence claim.

Statute of Limitations in Washington

In Washington, the statute of limitations for personal injury claims, including those related to prescription drug side effects, is generally three years from the date the injury was discovered or should have been discovered. This is known as the 'discovery rule.' For TD, the timeline between exposure and documented harm can be variable. Some patients develop symptoms within months, while others may not notice them for years. The discovery rule means that the clock starts ticking when the patient knew or reasonably should have known that their movements were caused by Reglan. This could be when a doctor diagnoses TD, or when the patient first notices abnormal movements and connects them to the medication. Settlement-related considerations for affected patients include the need to gather medical records documenting the Reglan prescription, the duration of use, and the diagnosis of TD. Evidence of the timeline between exposure and harm is crucial. For example, if a patient took Reglan for 18 months and developed TD two years later, the statute of limitations would likely begin at the time of diagnosis. Patients should also consider whether they received adequate warnings. If the prescribing physician did not discuss the risk of TD or the recommended 12-week limit, this could strengthen a claim. It is important to note that the statute of limitations can be complex, and exceptions may apply. For instance, if the patient was a minor at the time of exposure, the clock may be tolled until they reach adulthood. Additionally, if the drug manufacturer engaged in fraudulent concealment of risks, the statute may be extended. However, these are fact-specific issues that require legal advice.

Next Steps for Affected Patients

In summary, patients in Washington who developed TD after taking Reglan should be aware of the three-year statute of limitations from the date of discovery. The FDA labeling provides clear warnings about the risk of TD and the importance of short-term use, but many patients were not adequately informed. Gathering evidence of the prescription duration, the diagnosis, and the timeline of symptoms is essential for any potential settlement or lawsuit. Consulting with an attorney experienced in pharmaceutical litigation is strongly recommended to ensure that claims are filed within the applicable deadline.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to prescription drug side effects, is generally three years from the date the injury was discovered or should have been discovered. This is known as the 'discovery rule.' For tardive dyskinesia, the clock starts when the patient knew or reasonably should have known that their movements were caused by Reglan.

What evidence is needed to support a Reglan tardive dyskinesia claim?

Essential evidence includes medical records documenting the Reglan prescription, the duration of use, and a confirmed diagnosis of tardive dyskinesia. Also important is evidence of the timeline between exposure and harm, and whether the patient received adequate warnings about the risk of TD from their prescribing physician.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. DailyMed - Reglan Labeling

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.